Your session is about to expire
← Back to Search
tocilizumab for Heart Transplant
Study Summary
This trial is testing whether adding the drug tocilizumab to standard anti-rejection drugs can improve heart transplant outcomes.
Eligibility Criteria
Inclusion Criteria
You may be eligible if you check “Yes” for the criteria belowTimeline
Treatment Details
Study Objectives
Outcome measures can provide a clearer picture of what you can expect from a treatment.Side effects data
From 2012 Phase 4 trial • 91 Patients • NCT01163747Trial Design
Find a Location
Who is running the clinical trial?
Frequently Asked Questions
Has tocilizumab received the sign-off from the FDA?
"Our team has evaluated tocilizumab's safety and judged it a 2 because of the Phase 2 trial status. This indicates that there is some data attesting to its security but no evidence demonstrating efficacy."
How many hospitals and other medical facilities are offering this trial?
"Patients can be accepted into this clinical trial at numerous facilities, including Massachusetts General Hospital (MAMG) in Boston, MA, University of California San Diego: Sulpizio Cardiovascular Center (CASD) in La Jolla, CA., and Cedars Sinai Medical Center (CACS) in Beverly Hills FL. Additionally there are 18 other locations that may accept patients as well."
Could you please detail the previous experiments conducted utilizing tocilizumab?
"Presently, a total of 655 tocilizumab-related studies are in progress - with 146 being in late clinical trials. Philadelphia is the hotspot for these projects; however there are nearly 20,000 other sites running experiments related to this drug."
Is enrollment still available for this research endeavor?
"At present, this clinical trial is not enrolling any new participants. It was initially posted on December 20th 2018 and most recently updated on March 12th 2021. However, there are 10 studies actively recruiting cardiac transplant patients alongside an additional 655 tocilizumab trials seeking enrollees."
Does this study accommodate individuals over 25 years of age?
"The parameters of eligibility for this medical trial stipulate that the minimum age to participate is 18 and the ceiling age is 75."
How many subjects are taking part in the experiment?
"No longer accepting applicants, this trial was first posted on December 20th 2018 and the last update occurred 3rd of March 2021. If you are still looking for trials to enrol in, 10 cardiac transplant studies and 655 tocilizomab clinicals are currently recruiting patients."
What are the eligibility requirements for participating in this clinical experiment?
"This clinical trial is seeking 200 cardiac transplant recipients, aged between 18 and 75. In order for one to be eligible for the study they must adhere to a few conditions such as ascertaining an appropriate contraception method if applicable, being vaccinated against certain diseases when there are no contraindications, not undergoing any desensitization therapy prior to their heart transplantation."
For what medical purposes is tocilizumab prescribed?
"Tocilizumab is an approved therapy for scalp structure, thyroiditis, dermatitis and other forms of atopic conditions."
Share this study with friends
Copy Link
Messenger